A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell ...

Paycom's fundamentals face ongoing challenges, including cannibalization of growth by the BETI platform. Despite revenue growth in Q4 2023, there was deceleration and margin contraction due to ...

Last month’s news that Bluebird Bio had been hit with another hold on its sickle cell gene therapy was a deflating moment. But the firm, which has been dealt a number of setbacks, is pushing forward ...

Beti-cel gene therapy effectively achieves transfusion independence in transfusion-dependent β-thalassemia patients, consistent with clinical trial outcomes. The therapy was initially authorized in ...

Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up "Updated follow-up data of up to 10 ...

Paycom is a top revenue grower in the SaaS HCM industry, compounding sales at 20% annually over five years. Despite a 2023 setback due to Beti's cannibalization, Paycom is poised for growth with a 25% ...

Bluebird Bio will have to wait an extra three months to gain potential approvals for its breakthrough gene therapies beti-cel and eli-cel. The FDA has extended its review period for the lentiviral ...